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Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the
21st century. However, successful commercialization will require standardized manufacturing platforms.
Here we highlight the need to define standardized practices for iPSC generation and processing and discuss
current challenges to the robust manufacture of iPSC products.Introduction
Induced pluripotent stem cells (iPSCs) are
powerful tools for research and drug dis-
covery and may provide regenerative
therapies for diseases that conventional
medicine cannot cure presently. While
methods for generating iPSCs are contin-
ually evolving in the laboratory, and there
is substantial growth in patent activity in
the global iPSC landscape (Roberts
et al., 2014), significant hurdles remain
for successful commercial translation,
such as global harmonization of the regu-
latory landscape and attitudes to clinical
adoption. A fundamental requirement
for successful commercialization is the
ability to translate iPSC science to the
biomanufacturing community to createrobust and consistent high-quality iPSC
products at desired quantities that display
acceptable levels of comparability across
multiple lines.
As ‘‘living’’ products, cells pose a range
of biomanufacturing challenges. Vari-
ability in starting materials, process re-
agents, microenvironmental fluctuations,
and stochastic events within a cell popu-
lation, such as spontaneous cell cycle
arrest, create inconsistencies that are
challenging to control in manufacturing
processes. The challenges for creating
iPSC-based drug testing platforms or
therapeutics are particularly significant
because there are multiple methodolo-
gies for reprogramming cells to
create iPSCs. From a biomanufacturingCell Stem Cellperspective this creates significant vari-
ability in input materials along with pro-
cess variability that could translate to the
iPSC product that is generated. Subse-
quent processing to derive differentiated
target cell types that are comparable
would consequently be affected.
The need for stratified therapies is
driven by the heterogeneous nature of pa-
tients, not just in terms of disease status
but also genetic background. With global
efforts to generate large repositories of
iPSCs, effort is required to ensure that
the critical quality attributes of the result-
ing iPSCs meet consistent high quality.
If different reprograming methodologies
are used for producing iPSCs across
different repositories (and within a single16, January 8, 2015 ª2015 Elsevier Inc. 13
Figure 1. High-Level Process Map for iPSC Generation and Relationships between Operators and Processes
High level process map (A) outlining the transition of cell samples from raw input material to final product. In the case of the iPSC product, it is then itself an input
material for differentiation processes. The process is then presented below to highlight the unit operations required to deliver the downstream product. The rela-
tionship between operators, process, and infrastructure (B) is critical in the development of robust, standardized manufacturing strategies that reproducibility
yield material of consistent quality.
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from different sources may be chal-
lenging. Such discrepancies are problem-
atic because different cell product
characteristics arising from multiple ge-
netic backgrounds need to be understood
from a stratified medicine perspective in-
dependent of any product variation
arising from technical input variability.
Therefore, a robust and standardized
methodology will reduce the impact
of technical variability on the iPSC
product. A solid understanding of the
manufacturing processes and the rela-
tionship between key factors and their
impact on the cellular product is thus
needed (Figure 1).
Compared to protocols established in
individual research groups, stricter stan-
dards are needed to develop and validate
manufacturing processes and the associ-
ated iPSC banks (Turner et al., 2013). In
particular, there remains uncertainty
around the manufacturing and regulatory
challenges concerning human leukocyte
antigen-matched (HLA) master cell banks,14 Cell Stem Cell 16, January 8, 2015 ª2015in addition to regulatory and social uncer-
tainty around this new class of drug dis-
covery platform and therapeutic. With
many different methods available to
generate iPSCs, it is increasingly important
to define optimal manufacturing platforms
to meet the regulatory and quality assur-
ance demands of the biomanufacturing in-
dustrywhile alsominimizingcost of goods.
To this end, we highlight here various as-
pects of iPSC generation and processing
that must be considered for developing
standardized iPSC products.Current Technologies for iPSC
Generation
Significant global effort has been made to
developmethods to generate iPSCsmore
rapidly, safely, and efficiently. Increas-
ingly, such scientific advances are
yielding commercial products and ser-
vices; notably, Life Technologies (now ac-
quired by Thermo Fisher) has licensed
assay technologies for efficient genera-
tion (CytoTune-iPS 2.0) and characteriza-Elsevier Inc.tion/validation (TaqMan hPSC Scorecard)
of iPSCs.
Today, multiple methods can be used
to generate iPSCs (Figures 2 and S1)
and key publications of factors delivered
are reviewed elsewhere (Theunissen and
Jaenisch, 2014). Creating iPSCs that are
fit for purpose, either drug discovery or,
more challengingly, therapeutics, will
require a wide understanding of the bio-
logical characteristics and process condi-
tions. Critical considerations to meet
cGMP guidelines include cell line deriva-
tion, potential contaminants and adventi-
tious agents, desired features and how
these features can be assayed, and reli-
ability/reproducibility in the generation of
a safe and efficacious end-product. The
first major consideration for generating
iPSCs is, however, the choice of primary
cell source for reprogramming.Cell Material
Because primary cell ‘‘input’’ material is
typically heterogeneous, each single re-
programmed ‘‘output’’ cell might differ.
Figure 2. Delivery Methods for Molecular Reprogramming of Cells in the Generation of iPSCs
Numerous candidate technologies have potential applications in the manufacturing pathway to create iPSCs.
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the input material by pre-selecting a
particular cell subset (e.g., selecting
mesenchymal cells on the basis of a panel
of surface epitopes) could create a more
robust product. Although the field has
not yet settled on the optimum starting
cell for iPSC products, convincing argu-
ments have been made for using multipo-
tent stem cells, particularly those from
cord blood, which are highly unlikely to
have accumulated epigenetic changes,
pointmutations, or chromosomal damage
typical of older cells (Jacoby et al., 2012).
For the generation of disease-specific cell
lines for research purposes, however,
blood may be a better candidate due to
broader patient accessibility.
Aside from biological considerations,
the choice of source material will be influ-
enced to a large degree by the ease with
which it can be obtained from the donor
with informed consent for tissue/cell
removal, reprogramming, expansion,
and storage. The legal requirements to
cover ethical and regulatory standards
must be met before source tissue/cells
can be obtained—including informed
consent based on the understanding of
the full scope of iPSC generation
including commercial opportunities.Cell Reprograming
Advances in reprograming methods now
provide multiple vectors for gene delivery,
techniques that avoid the use of onco-
genic transgenes, and even DNA-free
methods (Figures 2 and S1).
Fundamental for manufacturing cell
therapies is product stability, which in
part underpins clinical safety. While
phenotypic stability will be challenging to
gauge when initially generating iPSC
banks, any measurable characteristics of
iPSCs that indicate genomic stability and
phenotypic fluctuations would greatly
facilitate future development of iPSC-
derived products. This is where a clear
distinction is drawn between integrating
vectors and non-integrating vectors and
DNA-free methods. Unlike integrating
vectors, non-integrating vectors achieve
reprogramming without inserting material
into the host genome and thus avoid the
risk of insertional mutagenesis.
Non-integrating episomes can achieve
reprogramming within 30 days, andmeth-
odologic improvements that bypass the
need for serial transfection (Yu et al.,
2011) have created one of the simplest
processes with minimal manual process-
ing that could be translated to automated
platformswith ease.Minicircle vectors areCell Stem Cellepisomes that lack plasmid backbones,
making them potentially advantageous in
terms of safety. However, overall reprog-
ramming efficiency of episomal methods
is low compared with other non-inte-
grating methods such as Sendai virus or
mRNA transfection.
The Sendai virus is also popular as
a non-integrating reprograming vector
because the method is simple and, when
temperature-sensitive Sendai viruses
such as that already used for c-myc
(Ban et al., 2011) are adopted, removal
of Sendai RNA from iPSCs by a tempera-
ture shift will be possible. Also based on
the Sendai virus, the CytoTune 2.0 kit
(Life Technologies) is available off-the-
shelf with validated protocols for gener-
ating stable transgene-free iPSCs with
little cytotoxicity and much more rapid
virus elimination than that enabled by pre-
vious kits. Suchmethods are not only very
amenable to process development but
would, if adopted as part of cGMP proto-
cols, also satisfy regulatory requirements
for therapeutics, where full removal of
viral material will be desirable or neces-
sary. The cost, however, remains high.
Direct delivery of mRNA or microRNA
(miRNA), which eliminates the use of
DNA and viruses, has been developed16, January 8, 2015 ª2015 Elsevier Inc. 15
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enous mRNA can be modified to dampen
cytotoxicity and antiviral defense mecha-
nisms in the cell (Warren et al., 2010).
This method can achieve one of the high-
est reprogramming efficiencies among
non-integrative techniques. Current
methodologies require daily transfection
but may be easily automated, making it
an exciting candidate for routine bio-
manufacture. Yet, work remains in
confirming the reproducibility and miti-
gating commercial risks before this meth-
odology can serve as a viable tool for
manufacturing iPSCs.
Total removal of nucleic acids for re-
programing by using peptide-based
delivery of transcription factors or small
molecules instead could utilize estab-
lished biomanufacturing pathways to
generate the reprograming material.
From a bioprocessing perspective, small
molecules are easier to define and control
for platform standardization and regula-
tory approval.
Process Optimization for
Reprograming iPSCs
In any stem cell manufacturing endeavor,
cost of reagents and media typically rep-
resents the most substantial fraction of
total production costs. Furthermore, bio-
processing operations traditionally rely
on iteratively optimizing each stage,which
adds significant cost and off-process
analysis requirements. Process optimiza-
tion using small-scale, high-throughput
testing devices that require microliter
quantities of culture media yet allow stan-
dardized comparative assessment of cell
product quality would greatly contribute
toward a commercially viable process.
Although still in the early stages of devel-
opment, such devices can provide real-
time or rapid readouts of cell product
attributes, using minimal cell numbers
and media in microbioreactor arrays.
These microdevices can be multiplexed,
permitting multiple bioprocessing param-
eters to be assessed in factorial or combi-
natorial manners, and are being used to
address gaps in our knowledge of each
process step, such as the impact ofmedia
exchange and shear stress, media
composition and timing of factor provi-
sion, and paracrine/autocrine signaling
on cellular behaviors and quality (Titmarsh
et al., 2013). Due to their flexibility and
portability, such microdevices have utility16 Cell Stem Cell 16, January 8, 2015 ª2015for pre-screening multiple cell inputs and
reprogramming reagents for the optimal
reprogramming regime that delivers
the most consistent quality product in
terms of transfection efficiency and yield,
which can subsequently be mathemati-
cally modeled as part of Quality by Design
engineering approaches to optimize
larger scale operations for subsequent
clinical-scale iPSC expansion. Finally,
theywould facilitate standardized product
testing of iPSCs from diverse genetic
backgrounds and could provide a plat-
form to perform comparability studies
with genetically diverse cells versus
gene-edited single pluripotent cell lines
that are not confounded by diverse ge-
netic backgrounds.
iPSC Selection and Validation
The cell reprogramming process is not
100%efficient andconsequently a hetero-
geneous mixture of iPSCs, partially
reprogrammedcells, andpartiallydifferen-
tiated cells is produced. Therefore, iPSCs
must be isolated from the mixed popula-
tion for further use. Many cell-sorting
methods, particularly those depending
on a single parameter, such as mor-
phology-based colony picking, may not
discern between partially reprogrammed
cells and iPSCs. Ideally, an industrial-
scale selection process would have the
capability to be replicated robustly and
the capacity to screen thousands of cell
lines with very high accuracy.
Selecting colonies based on mor-
phology is an option favored at lab-scale
due to the ability of well-trained operators
to identify appropriate colonies. It may
even be the best method for generating
different iPSC lines in parallel, given that
large numbers of cell lines need to be
generated from multiple primary sources
to cover the immunological variation
among patients. However, operator bias
is difficult to control and manual picking
is labor-intensive and, thus, prohibitive
at large scales (Meissner et al., 2007). Al-
gorithms for automated colony selection
based on morphology could remove
operator bias but would require signifi-
cant validation against the gold standard:
the eyes and expertise of a skilled
operator.
Incorporation of a reporter or selection
tool (e.g., antibiotic selection) to positively
select iPSCs is typically considered a
more accurate alternative to colony pick-Elsevier Inc.ing. However, adding a reporter/selection
tool may introduce additional risk, par-
ticularly in cells intended for therapeutic
use. Downstream elimination of re-
porters/selectors, using principles similar
to the temperature-sensitive Sendai virus,
may lower such risks, albeit with higher
process complexity.
The most accurate method for iPSC
identification is immunoselection based
on cell surface antigens using fluores-
cence- or magnetic-activated cell sorting.
These methods enable multiparametric
selection to a very high purity. Removal
of the selection antibodies will be impor-
tant for ensuring that iPSCs are biologi-
cally functional for subsequentprocessing
and directed differentiation. Even if clin-
ical-grade antibodies are used, removal
of sorting antibodies from the final product
may be required, especially in clinical ap-
plications, and the additional processing
will almost certainly impact cell quality.
The application of existing clinical-grade
cell sorting (e.g., Miltenyi CliniMACs)
offers a very sound platform for selection,
purification, and validation of iPSCs and
provides automated, closed-system,min-
imal handling capacity.
True confirmation of pluripotency typi-
cally uses an in vivo teratoma assay, re-
garded as the best validation method for
human iPSCs at present. However, this
gold standard is an expensive and labo-
rious assay, taking 2–3 months to
perform, and it’s hardly practical for
scale-up or high-throughput adoption.
In vitro assays that can conclusively
confirm pluripotency would substantially
streamline manufacturing of iPSCs.
Recent Q-PCR-based methods offer
rapid throughput and further analysis of
differentiation and are now possible using
the standardized TaqMan hPSC Score-
card (Life Technologies) by comparing
transcripts to a reference standard.
In vitro embryoid-body-based assays
that assess differentiation toward specific
lineages under optimized conditions are
also better suited to high-throughput,
with measurement of protein and tissue
induction in addition to that of gene tran-
scripts. However, in vitro gene transcrip-
tion and directed differentiation assays
may not be sufficient in the present regu-
latory environment. Recent developments
such as a novel in vitro teratoma assay
may offer unique solutions (Whitworth
et al., 2014).
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says to adequately characterize iPSCs
currently presents one of the biggest ob-
stacles to commercialization due to the
quantity and complexity of tests required.
The overarching goal of biomanufacturing
is to streamline validation processes by
reducing the number of assays, improving
assay efficiency without compromising
safety, or developing standardized as-
says to improve reproducibility between
different manufacturers. As our under-
standing of iPSCs increases, the possibil-
ity to rethink validation procedures will
advance, making the creation of produc-
tion platforms for cell banking more
feasible. Critically, we need to define a
robust set of criteria to ensure that a
consensus standard of quality is achieved
for cell therapy and drug discovery
applications.
Bottlenecks and Next Steps
Ultimately, the goal of generating iPSCs is
the identification and development of
novel therapies. Economically sound plat-
forms are necessary to give a high degree
of reproducibility for the production of
multiple iPSC lines. This would enable
the establishment of cell banks with qual-
ity-assured, off-the-shelf iPSC products
for multiple applications, while covering
the immunological diversity of the patient
pool. Current progress in this direction is
notable, though a substantial change is
still required in standards, cell line
manufacturing, and validation to support
an effective transition from research to
generation of clinical-grade iPSCs. Forproduction of universal iPSC banks, pro-
cess maps and product critical quality
attributesmust be clearly defined. This re-
mains the main bottleneck in advancing
iPSC banking because reprogramming
and validation methods are currently var-
ied and consensus is lacking. Outlining
appropriate regulator-informed process
maps that incorporate defined and
controllable process parameters at every
possible step will help to shape a bio-
manufacturing platform that delivers a
robust iPSC product of consistent quality.
In creating large iPSC banks, fundamental
science would benefit substantially from
the standardization of reprogramming
methods early on so that consistency
and reproducibility in the generation of
iPSC products can be achieved, both of
which are critical for successful commer-
cial translation.SUPPLEMENTAL INFORMATION
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